Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer

被引：7
|
作者：
Ecke, Thorsten H. [1 ]
机构：
[1] HELIOS Hosp, Dept Urol, Pieskower Str 33, D-15526 Bad Saarow Pieskow, Germany
来源：
ADVANCES IN CANCER BIOMARKERS: FROM BIOCHEMISTRY TO CLINIC FOR A CRITICAL REVISION | 2015年 / 867卷
关键词：
Adjuvant chemotherapy; Bax; Bcl-2; Biomarker; Bladder cancer; CD40; Chemotherapy; Cisplatin; C-reactive protein (CRP); Emmprin; ERCC1; HER2/neu; Human epidermal growth factor receptor 2 (HER-2); Ki-67; MDR1; Metallothionein (MT); p53; Smac/DIABLO; Survivin; Tissue polypeptide antigen (TPA); TLX3; gene; Transcription factor TFAP2 alpha; TRANSITIONAL-CELL-CARCINOMA; GROWTH-FACTOR RECEPTOR; TISSUE POLYPEPTIDE ANTIGEN; MESSENGER-RNA EXPRESSION; METASTATIC UROTHELIAL CARCINOMA; PROVIDE PROGNOSTIC INFORMATION; TYROSINE KINASE INHIBITORS; LONG-TERM SURVIVAL; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY;
D O I：
10.1007/978-94-017-7215-0_18
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The treatment of metastasized bladder cancer has been evolving during recent years. Cisplatin based chemotherapy combinations are still gold standard in the treatment of advanced and metastasized bladder cancer. But new therapies are approaching. Based to this fact biological markers will become more important for decisions in bladder cancer treatment. A systematic MEDLINE search of the key words "cisplatin", "bladder cancer", "DNA marker", "protein marker", "methylation biomarker", "predictive marker", "prognostic marker" has been made. This review aims to highlight the most relevant clinical and experimental studies investigating markers for metastasized transitional carcinoma of the urothelium treated by cisplatin based regimens.
引用
收藏
页码：293 / 316
页数：24
相关论文
共 50 条
  • [1] DNA Methylation as a Biomarker to predict Neoadjuvant Cisplatin-based Chemotherapy Resistance in Bladder Cancer
    Tan, W. S.
    de Winter, P.
    King, K.
    Gurung, P.
    Jameson, C.
    Freeman, A.
    Bryan, R.
    James, N.
    Beck, S.
    Kelly, J. D.
    Feber, A.
    BJU INTERNATIONAL, 2013, 111 : 63 - 63
  • [2] ACCELERATED CISPLATIN-BASED CHEMOTHERAPY FOR ADVANCED BLADDER-CANCER
    BOSHOFF, C
    OLIVER, RTD
    GALLAGHER, CJ
    ONG, J
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (10) : 1633 - 1636
  • [3] ELIGIBILITY OF PATIENTS WITH UROTHELIAL CANCER OF THE BLADDER FOR NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY
    Vemana, Goutham
    Sandhu, Gurdarshan
    Nepple, Kenneth
    Strope, Seth
    JOURNAL OF UROLOGY, 2013, 189 (04): : E54 - E54
  • [4] Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer
    Heidenreich, A
    Marx, FJ
    Peters, HJ
    UROLOGE-AUSGABE A, 1999, 38 (06): : 586 - 591
  • [5] Thromboembolic events with cisplatin-based neoadjuvant chemotherapy for transitional cell carcinoma of urinary bladder
    Botten, Joanne
    Sephton, Matt
    Tillett, Tania
    Masson, Susan
    Thanvi, Narottam
    Herbert, Christopher
    Hilman, Serena
    Rowe, Edward
    Gillatt, David
    Persad, Raj
    Whittlestone, Tim
    Bahl, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [6] NOVEL BIOMARKER SIGNATURE FOR PREDICTING PATHOLOGIC RESPONSE OF UROTHELIAL CARCINOMA OF THE BLADDER TO CISPLATIN-BASED NEOADJUVANT CHEMOTHERAPY
    Hensley, Patrick
    Purdom, Matthew
    Kyprianou, Natasha
    Wang, Chi
    James, Andrew
    JOURNAL OF UROLOGY, 2018, 199 (04): : E864 - E865
  • [7] Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy
    Hensley, Patrick J.
    Kyprianou, Natasha
    Purdom, Matthew S.
    He, Daheng
    DiCarlo, Vincent
    Wang, Chi
    James, Andrew C.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (09) : 572.e1 - 572.e11
  • [8] Perioperative cisplatin-based chemotherapy for muscle-invasive bladder cancer: a decision analysis
    Afferi, Luca
    Jahn, Beate
    Kelkar, Amar H.
    Dijk, Stijntje W.
    Feldman, Zach M.
    Ward, Zachary J.
    Moschini, Marco
    Cathomas, Richard
    Bellmunt, Joaquim
    Gallioli, Andrea
    Breda, Alberto
    Fankhauser, Christian D.
    Mattei, Agostino
    Chang, Steven L.
    Siebert, Uwe
    WORLD JOURNAL OF UROLOGY, 2025, 43 (01)
  • [9] Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer
    Gil Jimenez, Albert
    van Dorp, Jeroen
    Contreras-Sanz, Alberto
    van der Vos, Kristan
    Vis, Daniel J.
    Braaf, Linde
    Broeks, Annegien
    Kerkhoven, Ron
    van Kessel, Kim E. M.
    Ribal, Maria Jose
    Alcaraz, Antonio
    Wessels, Lodewyk F. A.
    Seiler, Roland
    Wright, Jonathan L.
    Mengual, Lourdes
    Boormans, Joost
    van Rhijn, Bas W. G.
    Black, Peter C.
    van der Heijden, Michiel S.
    EUROPEAN UROLOGY, 2023, 83 (04) : 313 - 317
  • [10] EFFECTIVENESS OF COMBINATION CISPLATIN-BASED INTRAVESICAL CHEMOTHERAPY FOR BCG-REFRACTORY BLADDER CANCER
    Vila-Reyes, Helena
    Decastro, G. Joel
    Faiena, Izak
    Pak, Jamie S.
    Lee, Kevin
    Li, Gen
    Anderson, Christopher B.
    Abate-Shen, Cory T.
    McKiernan, James M.
    JOURNAL OF UROLOGY, 2020, 203 : E1124 - E1124
12345